ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Blood-based multi-cancer early detection (MCED) technologies hold the promise to revolutionize America’s cancer-screening paradigm, dramatically expanding the range of detectable cancers and identifying them at earlier stages when cancers are more treatable. Policymakers should provide a supportive regulatory and coverage environment.

On May 18, 2017, Stephen Ezell gave a presentation before the Rare Disease Congressional Caucus on "Incentivizing Innovation for Rare Disease Treatment and Development."

Incentivizing Innovation for Rare Disease Treatment and Development

Stephen Ezell will be speaking at the James Madison Institute’s Florida Tech & Innovation 2022 Summit in Coral Gables, Florida on a panel discussing “Innovations and the Future of Healthcare.”

Innovations and the Future of Healthcare

Multi-cancer early detection (MCED) technologies are poised to radically transform the cancer-screening paradigm for the significant benefit of Americans’ individual and public health. Congress can play a critical role in making that transformation happen.

Testimony to the House Energy and Commerce Subcommittee on Health Regarding Seniors’ Access to Breakthrough Medical Technologies

Testimony to the House Energy and Commerce Subcommittee on Health Regarding Seniors' Access to Breakthrough Medical Technologies

A new class of blood-based multi-cancer early detection (MCED) technologies promise to revolutionize the cancer-screening paradigm by marshaling the power of next-generation gene sequencing, artificial intelligence, and big data to dramatically expand the range of detectable cancers while identifying them at earlier stages when they are much more treatable.

New ITIF Report: Emerging Technologies That Detect More Cancers at Earlier Stages Need Regulatory Support for Public to Benefit

Congress should provide a pathway for Medicare to cover multi-cancer early detection (MCED) screening tests that expand the range of detectable cancers and identify them earlier, when cancers are more treatable.

To Do: Cover Multi-Cancer Early Detection Tests Under Medicare

Again and again, America has pioneered new technologies and then frittered away its leadership—in sectors ranging from semiconductors and solar panels, to televisions and medical devices. We can’t afford to squander another lead in multi-cancer early detection (MCED) because of regulatory roadblocks.

America Can’t Afford to Lose the Early Cancer Detection Race to China

Stephen Ezell gave a presentation on global best practices in Technology Transfer and Commercialization at the 2016 Bio Conference on June 6, 2016.

Best Practices in Commercialization and Technology Transfer

Stephen Ezell gave a presentation on “Seizing the Transformative Opportunity of Multi-cancer Early Detection” at the 15th Annual Next Generation Dx Summit.

Stephen Ezell gave a presentation on “Seizing the Transformative Opportunity of Multi-cancer Early Detection” at the 15th Annual Next Generation Dx Summit in Washington, DC on August 22, 2023.

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Related